Clinical TrialMay 7, 2026, 04:01 PM
Assembly Bio Completes Phase 1b Herpes Studies; Q4 2026 Phase 2 HDV Start
AI Summary
Assembly Biosciences reported steady progress in its clinical pipeline, completing Phase 1b studies for ABI-5366 and ABI-1179 for recurrent genital herpes, and chronic toxicology studies for ABI-6250 for chronic hepatitis delta virus, with Phase 2 initiation for ABI-6250 expected in Q4 2026. The company also anticipates receiving Gilead's development plan for the herpesvirus program by mid-2026 to evaluate a cost and profit share opt-in decision. For Q1 2026, Assembly Bio reported a net loss of $9.1 million on revenue of $8.2 million, with a cash position of $226.6 million projected to fund operations into 2028.
Key Highlights
- Phase 1b studies for ABI-5366 and ABI-1179 completed for recurrent genital herpes.
- Chronic toxicology studies for ABI-6250 completed; Phase 2 HDV initiation anticipated Q4 2026.
- Gilead development plan for herpes program expected mid-2026 for opt-in decision.
- Cash, cash equivalents, and marketable securities were $226.6 million as of March 31, 2026.
- Projected cash position to fund operations into 2028.
- Q1 2026 revenue from collaboration with Gilead was $8.2 million, down from $9.4 million YoY.
- Q1 2026 net loss was $9.1 million, or $0.54 per share.